tirzepatide shortage update 🚨 Alert: No Longer on FDA's Drug List As of October 2, 2024, the FDA has announced that the Tirzepatide shortage has been resolved. This means that all doses of ⚠️Medicine shortage update - Discontinuation

80,101 Linaclotide approval in the United States was based on the results of 2 phase 3 studies (NCT00938717 92 and NCT00948818 93 ), which showed that oral linaclotide 290 g once daily was safe and effective for relieving symptoms in patients with IBS-C

doi:10.1056/nejmoa2206038 7Wilding JPH, Batterham RL, Davies M, et al

Beyond weight loss, taking tirzepatide can bring improvements in metabolic health, lower blood sugar, and normalize cholesterol levels

Staying hydrated, eating smaller, protein-rich meals, and avoiding high-fat or high-fiber foods immediately after dose increases can substantially reduce discomfort

The compound is currently in the development pipeline, with Eli Lilly, the pharmaceutical company behind its creation, actively pursuing the next stages of the regulatory process

Through Your Primary Care Physician Your existing doctor is often the most straightforward starting point